N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
• 化学式: C₁₄H₁₂N₄O
• 分子量: 252.275
• InChiKey: GTMGQYXCPKUZAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,6-二氨基-2-溴烟腈 在 吡啶 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
  参考文献：
  名称：

  Aminopyridine-Based c-Jun N-Terminal Kinase Inhibitors with Cellular Activity and Minimal Cross-Kinase Activity

  摘要：

  The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1,000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38alpha, and p38delta and showed little inhibitory activity against a panel of 74 kinases.

  DOI：

  10.1021/jm060199b

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• Inhibitors of c-jun N-terminal kinases
  申请人：Abbott Laboratories

  公开号：US07888374B2

  公开（公告）日：2011-02-15

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及一类抑制c-jun N末端激酶1、2或3（JNK1、JNK2或JNK3）的化合物，包含该化合物的组合物以及在预防或治疗受JNK1、JNK2和JNK3激活调节的疾病中使用该化合物的方法。
• US7888374B2
  申请人：——

  公开号：US7888374B2

  公开（公告）日：2011-02-15
• [EN] INHIBITORS OF C-JUN N-TERMINAL KINASES<br/>[FR] INHIBITEURS DES C-JUN N-TERMINAL KINASES
  申请人：ABBOTT LAB

  公开号：WO2006083673A2

  公开（公告）日：2006-08-10

  [EN] The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.
  [FR] L'invention porte sur des composés qui sont des inhibiteurs de la c-jun N-terminal kinase 1, 2 ou 3 (JNK1, JNK2, ou JNK3), sur des compositions contenant lesdits composés et sur l'utilisation des composés dans la prévention ou le traitement des troubles régulés par l'activation de JNK1, JNK2 et JNK3.
• Aminopyridine-Based c-Jun N-Terminal Kinase Inhibitors with Cellular Activity and Minimal Cross-Kinase Activity
  作者：Bruce G. Szczepankiewicz、Christi Kosogof、Lissa T. J. Nelson、Gang Liu、Bo Liu、Hongyu Zhao、Michael D. Serby、Zhili Xin、Mei Liu、Rebecca J. Gum、Deanna L. Haasch、Sanyi Wang、Jill E. Clampit、Eric F. Johnson、Thomas H. Lubben、Michael A. Stashko、Edward T. Olejniczak、Chaohong Sun、Sarah A. Dorwin、Kristi Haskins、Cele Abad-Zapatero、Elizabeth H. Fry、Charles W. Hutchins、Hing L. Sham、Cristina M. Rondinone、James M. Trevillyan

  DOI：10.1021/jm060199b

  日期：2006.6.1

  The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1,000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38alpha, and p38delta and showed little inhibitory activity against a panel of 74 kinases.